Low-exhaustion peripheral circulating γδ T cells serve as a biomarker for predicting the clinical benefit rate of non-small cell lung cancer (NSCLC) patients to chemotherapy or targeted therapy: a single-center retrospective study

作     者：Zhang, Dongdong Liu, Guichao Ye, Jinhui Li, Ke Zhang, Guojun Quan, Qiang Zhu, Xinhai Li, Peng 

作者机构：Jinan Univ Affiliated Hosp 1 Dept Thorac Surg Guangzhou Peoples R China Jinan Univ Affiliated Hosp 1 Res Ctr Canc Diag & Therapy Dept Oncol Guangzhou Peoples R China First Peoples Hosp Foshan City Dept Radiat Oncol Foshan Peoples R China First Peoples Hosp Zhaoqing Dept Breast Oncol Zhaoqing Peoples R China Sun Yat Sen Univ Affiliated Hosp 7 Dept Geriatr Shenzhen Peoples R China Hosp Southern Univ Sci & Technol Dept Clin Nutr Shenzhen Peoples R China Jinan Univ Zhuhai Peoples Hosp Zhuhai Inst Translat Med Guangdong Prov Key Lab Tumor Intervent Diag & Trea Zhuhai Peoples R China Jinan Univ Biomed Translat Res Inst Fac Med Sci Guangzhou Peoples R China 

出 版 物：《BMC CANCER》 (BMC Cancer)

年 卷 期：2025年第25卷第1期

页      面：1-11页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Shenzhen Science and Technology Program 

主　　题：gamma delta T cell Immune exhaustion NSCLC Chemotherapy Targeted therapy 

摘      要：BackgroundMultiple studies have demonstrated that the abundance and functionality of gamma delta T cells are favorable prognostic indicators for prolonged survival in cancer patients. However, the association between the immunophenotype of circulating gamma delta T cells and the therapeutic response in NSCLC patients undergoing chemotherapy or targeted therapy remains *** with EGFR wild-type (EGFR-WT) or mutant (EGFR-Mut) non-small cell lung cancer (NSCLC), diagnosed between January 2020 and January 2024, were included in this study. Clinicopathological characteristics, treatment regimens, and follow-up data were retrospectively collected. Peripheral blood samples from 52 NSCLC patients were analyzed for the immunophenotypes of alpha beta T cells and gamma delta T cells using full-spectrum flow *** significant differences were observed in the proportions of alpha beta T cells or gamma delta T cells, nor in the expression of immune exhaustion markers, between epidermal growth factor receptor wild-type and mutant NSCLC patients. Notably, NSCLC patients with a high clinical benefit rate (responder, R) exhibited a higher proportion of circulating V delta 2 T cells compared to non-responders (NR), in both EGFR-Mut (NR vs. R, P = 0.0437) and EGFR-WT groups (NR vs. R, P = 0.0180). Additionally, the expression of the immune exhaustion marker PD-1 on V delta 2 T cells was significantly lower in the responder group (NR vs. R, EGFR-Mut, P = 0.0050;EGFR-WT, P = 0.0180). Moreover, responder patients exhibited elevated levels of TNF-alpha compared to non-responders, irrespective of EGFR mutation status (NR vs. R, EGFR-Mut, P = 0.0055;EGFR-WT, P = 0.0007).ConclusionsThese findings collectively suggest that circulating V delta 2 T cells with low levels of immune exhaustion are critical contributors to the effectiveness of chemotherapy and targeted therapies in NSCLC. Targeting V delta 2 T cells may represent a promising strategy for enhancing the